Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature

Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, mos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapur, Sakshi, Xiao, Han, Zakowski, Maureen F., Hameed, Meera R., Levin, Miles B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649879/
https://www.ncbi.nlm.nih.gov/pubmed/29147383
http://dx.doi.org/10.14740/wjon779w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649879/
https://www.ncbi.nlm.nih.gov/pubmed/29147383
http://dx.doi.org/10.14740/wjon779w

Ejemplares similares